Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Acta Pharmacol Sin ; 42(7): 1101-1110, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-33028983

RESUMO

Alcoholic liver disease (ALD) is one of the pathogenic factors of chronic liver disease with the highest clinical morbidity worldwide. Ursolic acid (UA), a pentacyclic terpenoid carboxylic acid, has shown many health benefits including antioxidative, anti-inflammatory, anticancer, and hepatoprotective activities. We previously found that UA was metabolized in vivo into epoxy-modified UA containing an epoxy electrophilic group and had the potential to react with nucleophilic groups. In this study we prepared an alkynyl-modified UA (AM-UA) probe for tracing and capturing the target protein of UA from liver in mice, then investigated the mode by which UA bound to its target in vivo. By conducting proteome identification and bioinformatics analysis, we identified caspase-3 (CASP3) as the primary target protein of UA associated with liver protection. Molecule docking analysis showed that the epoxy group of the UA metabolite reacted with Cys-163 of CASP3, forming a covalent bond with CASP3. The binding mode of the UA metabolites (UA, CM-UA, and EM-UA) was verified by biochemical evaluation, demonstrating that the epoxy group produced by metabolism played an important role in the inhibition of CASP3. In alcohol-treated HepG2 cells, pretreatment with the UA metabolite (10 µM) irreversibly inhibited CASP3 activities, and subsequently decreased the cleavage of PARP and cell apoptosis. Finally, pre-administration of UA (20-80 mg· kg-1 per day, ig, for 1 week) dose-dependently alleviated alcohol-induced liver injury in mice mainly via the inhibition of CASP3. In conclusion, this study demonstrates that UA is a valuable lead compound for the treatment of ALD.


Assuntos
Apoptose/efeitos dos fármacos , Caspase 3/metabolismo , Inibidores de Caspase/uso terapêutico , Hepatopatias Alcoólicas/tratamento farmacológico , Fígado/efeitos dos fármacos , Triterpenos/uso terapêutico , Sequência de Aminoácidos , Animais , Caspase 3/química , Inibidores de Caspase/metabolismo , Cisteína/química , Compostos de Epóxi/química , Compostos de Epóxi/uso terapêutico , Células Hep G2 , Hepatócitos/efeitos dos fármacos , Humanos , Fígado/enzimologia , Fígado/patologia , Hepatopatias Alcoólicas/enzimologia , Hepatopatias Alcoólicas/patologia , Masculino , Camundongos , Simulação de Acoplamento Molecular , Poli(ADP-Ribose) Polimerases/metabolismo , Ligação Proteica , Alinhamento de Sequência , Triterpenos/metabolismo , Ácido Ursólico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...